Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1208/aapsj070103 http://scihub22266oqcxt.onion/10.1208/aapsj070103 16146335Propertiesofthalidomideanditsanalogues:Implicationsforanticancertherapy.!2751493!16146335     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       AAPS+J 2005 ; 7 (1): E14-9 Nephropedia Template TP {{tp|p=16146335|t=2005. Properties of thalidomide and its analogues: implications for anticancer therapy |pdf=|usr=}}{{16146335}} gab.com Text Properties of thalidomide and its analogues: implications for anticancer therapy JO: AAPS J http://www.kidney.de/pget.php?&tw=1&pmid=16146335 #FOAvip Thalidomide and its immunomodulatory (IMiDs) analogs (lenalidomide, Revlimid, CC-5013; CC-4047, ACTIMID) are a novel class of compounds with numerous effects on the body's immune system, some of which are thought to mediate the anticancer and anti-inflammatory results observed in humans. Thalidomide is currently being used experimentally to treat various cancers and inflammatory diseases. It is approved for the treatment of dermal reaction from leprosy and is currently in phase III trials for multiple myeloma. Thalidomide and IMiDs inhibit the cytokines tumor necrosis factor-alpha (TNF-alpha), interleukins (IL) 1beta, 6, 12, and granulocyte macrophage-colony stimulating factor (GM-CSF). They also costimulate primary human T lymphocytes inducing their proliferation, cytokine production, and cytotoxic activity thereby increasing the T cells' anticancer activity. They induce an IL-2-mediated primary T cell proliferation with a concomitant increase in IFN-gamma production and decrease the density of TNF-alpha-induced cell surface adhesion molecules ICAM-1, VCAM-1, and E-selectin on human umbilical vein endothelial cells. Thalidomide stimulates the Th-1 response increasing IFN-gamma levels while CC-4047 increased IL-2 as well. Some of the above immunomodulatory activities along with anti-angiogenic, anti-proliferative, and pro-apoptotic properties are thought to mediate the IMiDs' antitumor responses observed in relapsed and refractory multiple myeloma and some solid tumor cancers. This has led to their use in various oncology clinical trials. The second generation IMiD, lenalidomide, has shown potential in treating the bone marrow disorders myelodysplastic syndrome and multiple myeloma. It is currently in phase II and III trials for these diseases respectively with numerous phase II trials in other hematologic and solid tumors. Twit Text FOAVip Properties of thalidomide and its analogues: implications for anticancer therapy ????AAPS J http://www.kidney.de/pget.php?&tw=1&pmid=16146335 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=16146335 #FOAvip English Wikipedia <ref>{{Cite pmid|16146335}}</ref> Properties of thalidomide and its analogues: implications for anticancer therapy #MMPMID16146335 Teo SK AAPS J 2005[Mar]; 7 (1): E14-9 PMID16146335show ga Thalidomide and its immunomodulatory (IMiDs) analogs (lenalidomide, Revlimid, CC-5013; CC-4047, ACTIMID) are a novel class of compounds with numerous effects on the body's immune system, some of which are thought to mediate the anticancer and anti-inflammatory results observed in humans. Thalidomide is currently being used experimentally to treat various cancers and inflammatory diseases. It is approved for the treatment of dermal reaction from leprosy and is currently in phase III trials for multiple myeloma. Thalidomide and IMiDs inhibit the cytokines tumor necrosis factor-alpha (TNF-alpha), interleukins (IL) 1beta, 6, 12, and granulocyte macrophage-colony stimulating factor (GM-CSF). They also costimulate primary human T lymphocytes inducing their proliferation, cytokine production, and cytotoxic activity thereby increasing the T cells' anticancer activity. They induce an IL-2-mediated primary T cell proliferation with a concomitant increase in IFN-gamma production and decrease the density of TNF-alpha-induced cell surface adhesion molecules ICAM-1, VCAM-1, and E-selectin on human umbilical vein endothelial cells. Thalidomide stimulates the Th-1 response increasing IFN-gamma levels while CC-4047 increased IL-2 as well. Some of the above immunomodulatory activities along with anti-angiogenic, anti-proliferative, and pro-apoptotic properties are thought to mediate the IMiDs' antitumor responses observed in relapsed and refractory multiple myeloma and some solid tumor cancers. This has led to their use in various oncology clinical trials. The second generation IMiD, lenalidomide, has shown potential in treating the bone marrow disorders myelodysplastic syndrome and multiple myeloma. It is currently in phase II and III trials for these diseases respectively with numerous phase II trials in other hematologic and solid tumors. |Angiogenesis Inhibitors/pharmacology/therapeutic use[MESH] |Antineoplastic Agents/*pharmacology/therapeutic use[MESH] |Apoptosis/drug effects[MESH] |Cell Adhesion Molecules/metabolism[MESH] |Clinical Trials, Phase II as Topic[MESH] |Clinical Trials, Phase III as Topic[MESH] |Cytokines/antagonists & inhibitors[MESH] |Drug Screening Assays, Antitumor[MESH] |Endothelium, Vascular/drug effects/metabolism[MESH] |Humans[MESH] |Immunologic Factors/*pharmacology/therapeutic use[MESH] |Interferon-gamma/metabolism[MESH] |Interleukin-2/metabolism[MESH] |Killer Cells, Natural/drug effects[MESH] |Lenalidomide[MESH] |Lymphocyte Activation/drug effects[MESH] |Multiple Myeloma/drug therapy[MESH] |Myelodysplastic Syndromes/drug therapy[MESH] |Neoplasms/blood supply/*drug therapy/immunology[MESH] |T-Lymphocyte Subsets/drug effects/immunology/metabolism[MESH]Properties of thalidomide and its analogues: implications for anticanc(epmc).pdf DeepDyve Pubget Overpricing